Neurizon advances NUZ-001 as first ALS participant enters active extension

First participant enters NUZ-001 active treatment extension

Neurizon Therapeutics Limited (ASX:NUZ; OTCQB: NUZTF) has reached the next clinical milestone in its NUZ-001 program, with the first participant in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial completing the 36-week randomised controlled phase and moving into an optional Active Treatment Extension.

The extension gives eligible participants access to investigational NUZ-001 regardless of whether they originally received the drug or placebo. Treatment assignments remain blinded, and participants will continue regular assessments covering safety, respiratory function, quality of life, ALS Functional Rating Scale-Revised scores and biomarkers including neurofilament light chain.

Extension adds longer-term observations, not a new efficacy test

Neurizon said the additional treatment period is intended to build longer-term safety, tolerability, functional and biomarker data alongside the controlled trial dataset. It is not a separate controlled assessment of efficacy, and the usefulness of the extension data in any future regulatory submission remains subject to applicable requirements.

Regimen I is fully enrolled, with 250 participants recruited across 78 activated US clinical sites in about five months. The company expects topline results from the 36-week randomised phase in late Q2 CY2027. That readout remains the central test of whether the program can advance beyond its current investigational status.

FDA feedback gives the readout greater regulatory importance

The transition into the extension comes after the FDA indicated that positive HEALEY ALS results could support a traditional approval pathway, with Regimen I potentially serving as a single registrational study for a New Drug Application. That position is conditional: the trial results and any confirmatory evidence would still need to meet applicable regulatory requirements. The company’s earlier FDA approval pathway feedback described the same potential route ahead of the expected 2027 readout.

For now, the announcement reports no efficacy results. The immediate milestones are completion of the randomised phase, database lock and the topline release, followed by regulatory engagement with the FDA and other relevant authorities. The company has also recently positioned its finances around the trial timetable through a $4.3 million equity placement, but the clinical outcome remains the decisive uncertainty.